Previous Close | 6.74 |
Open | 6.67 |
Bid | 6.72 x 1800 |
Ask | 7.10 x 900 |
Day's Range | 6.42 - 7.07 |
52 Week Range | 4.68 - 19.22 |
Volume | |
Avg. Volume | 4,603,339 |
Market Cap | 381.164M |
Beta (5Y Monthly) | 1.12 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -9.96 |
Earnings Date | Sep 21, 2022 - Sep 26, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Oct 14, 1999 |
1y Target Est | 5.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for RAD
Why Rite Aid's (NYSE: RAD) stock pop and raised guidance still aren't enough to get him interested in buying shares. Additionally, with shares down nearly 70% over the past year, is Zoom Video Communications (NASDAQ: ZM) a screaming buy or past its prime? To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center.
Yahoo Finance Live anchors discuss third-quarter earnings for Walgreens.
PHILADELPHIA, June 30, 2022--Elixir, a wholly owned subsidiary of Rite Aid (NYSE: RAD), announced the launch of a specialty generic medication enhancement to its managed copay solutions effective June 1, 2022. The enhancement allows members to receive generic versions of certain specialty medications at a $0 copay and has the potential to provide an average savings of up to $40,000 annually.